Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
Myeloproliferative Disorders | 7 | 2021 | 507 | 2.48 | Why? |
Primary Myelofibrosis | 12 | 2019 | 144 | 2.38 | Why? |
Thrombocythemia, Essential | 10 | 2021 | 141 | 2.06 | Why? |
Polycythemia Vera | 10 | 2019 | 113 | 2.03 | Why? |
Serum Amyloid P-Component | 3 | 2021 | 193 | 1.55 | Why? |
Hematopoietic Stem Cell Transplantation | 17 | 2019 | 2426 | 1.32 | Why? |
Janus Kinase 2 | 5 | 2017 | 218 | 1.26 | Why? |
Leukemia, Myeloid, Acute | 6 | 2021 | 676 | 1.00 | Why? |
Neoplasm, Residual | 3 | 2017 | 147 | 0.97 | Why? |
Cytokine-Induced Killer Cells | 2 | 2018 | 8 | 0.91 | Why? |
Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1573 | 0.89 | Why? |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 526 | 0.85 | Why? |
Complement Pathway, Mannose-Binding Lectin | 1 | 2020 | 44 | 0.84 | Why? |
Transplantation, Homologous | 12 | 2019 | 757 | 0.73 | Why? |
Chromosome Aberrations | 2 | 2018 | 54 | 0.70 | Why? |
Lymphoma, Non-Hodgkin | 1 | 2021 | 403 | 0.69 | Why? |
Lymphocyte Transfusion | 1 | 2017 | 26 | 0.69 | Why? |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2018 | 314 | 0.68 | Why? |
Calreticulin | 1 | 2017 | 38 | 0.67 | Why? |
Mutation | 10 | 2018 | 12376 | 0.63 | Why? |
Thrombotic Microangiopathies | 1 | 2020 | 335 | 0.63 | Why? |
Pyrazoles | 5 | 2021 | 1791 | 0.62 | Why? |
C-Reactive Protein | 4 | 2021 | 7972 | 0.61 | Why? |
Drugs, Investigational | 1 | 2018 | 198 | 0.60 | Why? |
Hodgkin Disease | 1 | 2018 | 204 | 0.59 | Why? |
Interleukin-8 | 1 | 2021 | 964 | 0.58 | Why? |
Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 176 | 0.56 | Why? |
Withholding Treatment | 1 | 2021 | 798 | 0.55 | Why? |
Drug Resistance, Neoplasm | 2 | 2018 | 447 | 0.55 | Why? |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 82 | 0.50 | Why? |
Philadelphia Chromosome | 4 | 2019 | 38 | 0.49 | Why? |
Antineoplastic Agents | 7 | 2020 | 3550 | 0.47 | Why? |
Rituximab | 3 | 2017 | 1096 | 0.47 | Why? |
Antibodies, Monoclonal | 4 | 2021 | 8041 | 0.47 | Why? |
Multiple Myeloma | 2 | 2018 | 1064 | 0.47 | Why? |
Antibodies, Bispecific | 3 | 2018 | 207 | 0.44 | Why? |
Protein Kinase Inhibitors | 3 | 2020 | 1585 | 0.39 | Why? |
Endothelium, Vascular | 1 | 2020 | 1751 | 0.37 | Why? |
Ventilators, Mechanical | 1 | 2021 | 2193 | 0.37 | Why? |
Stem Cell Transplantation | 4 | 2017 | 531 | 0.34 | Why? |
Graft vs Host Disease | 4 | 2018 | 501 | 0.33 | Why? |
Cyclophosphamide | 2 | 2019 | 387 | 0.31 | Why? |
Chromosome Deletion | 2 | 2017 | 62 | 0.31 | Why? |
Transplantation Conditioning | 2 | 2017 | 323 | 0.29 | Why? |
Doxorubicin | 2 | 2018 | 313 | 0.29 | Why? |
Pyrimidines | 6 | 2021 | 1557 | 0.28 | Why? |
Antibodies, Monoclonal, Murine-Derived | 2 | 2016 | 94 | 0.28 | Why? |
Disease-Free Survival | 6 | 2019 | 1654 | 0.28 | Why? |
Myelodysplastic Syndromes | 2 | 2017 | 261 | 0.27 | Why? |
Leukemia | 3 | 2018 | 598 | 0.27 | Why? |
Antineoplastic Agents, Immunological | 3 | 2021 | 830 | 0.26 | Why? |
Prognosis | 14 | 2021 | 32490 | 0.25 | Why? |
Remission Induction | 4 | 2018 | 950 | 0.23 | Why? |
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 877 | 0.23 | Why? |
Cytogenetic Analysis | 2 | 2017 | 21 | 0.23 | Why? |
Hematologic Neoplasms | 3 | 2021 | 2105 | 0.23 | Why? |
Salvage Therapy | 3 | 2018 | 417 | 0.22 | Why? |
Homozygote | 2 | 2016 | 230 | 0.22 | Why? |
Survival Rate | 6 | 2021 | 9206 | 0.22 | Why? |
Mannose-Binding Protein-Associated Serine Proteases | 1 | 2020 | 41 | 0.22 | Why? |
Bone Marrow Neoplasms | 1 | 2021 | 60 | 0.21 | Why? |
Inflammation | 3 | 2020 | 13255 | 0.21 | Why? |
Biomarkers, Tumor | 3 | 2018 | 1314 | 0.21 | Why? |
Nitriles | 3 | 2021 | 1053 | 0.21 | Why? |
Acute Disease | 6 | 2021 | 6029 | 0.20 | Why? |
Gene Expression Profiling | 3 | 2020 | 3788 | 0.20 | Why? |
Phenotype | 4 | 2018 | 4037 | 0.20 | Why? |
Heparin Lyase | 1 | 2018 | 7 | 0.19 | Why? |
Genetic Association Studies | 3 | 2018 | 559 | 0.19 | Why? |
Vinblastine | 1 | 2018 | 48 | 0.19 | Why? |
Antilymphocyte Serum | 1 | 2018 | 80 | 0.19 | Why? |
Dacarbazine | 1 | 2018 | 67 | 0.18 | Why? |
Repressor Proteins | 2 | 2017 | 232 | 0.18 | Why? |
Survival Analysis | 5 | 2018 | 7592 | 0.18 | Why? |
Middle Aged | 38 | 2021 | 270681 | 0.18 | Why? |
Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 86 | 0.18 | Why? |
Chromosomes, Human, Pair 5 | 1 | 2017 | 38 | 0.18 | Why? |
Neoplasms, Second Primary | 1 | 2019 | 100 | 0.18 | Why? |
Cyclin-Dependent Kinase 6 | 1 | 2017 | 43 | 0.18 | Why? |
Natural Cytotoxicity Triggering Receptor 3 | 1 | 2017 | 14 | 0.18 | Why? |
Blast Crisis | 1 | 2018 | 41 | 0.18 | Why? |
B7 Antigens | 1 | 2017 | 18 | 0.18 | Why? |
DNA Mutational Analysis | 2 | 2017 | 581 | 0.18 | Why? |
Prostaglandin D2 | 1 | 2017 | 24 | 0.18 | Why? |
Clonal Evolution | 1 | 2017 | 55 | 0.17 | Why? |
Tetrahydroisoquinolines | 1 | 2017 | 12 | 0.17 | Why? |
Recurrence | 5 | 2019 | 3675 | 0.17 | Why? |
Dioxoles | 1 | 2017 | 19 | 0.17 | Why? |
Treatment Outcome | 10 | 2021 | 51732 | 0.17 | Why? |
CCAAT-Enhancer-Binding Protein-alpha | 1 | 2016 | 11 | 0.17 | Why? |
Leukemia, Myelomonocytic, Juvenile | 1 | 2017 | 27 | 0.17 | Why? |
Bleomycin | 1 | 2018 | 195 | 0.17 | Why? |
Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 127 | 0.17 | Why? |
Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 37 | 0.17 | Why? |
Antineoplastic Agents, Alkylating | 1 | 2017 | 71 | 0.16 | Why? |
Vincristine | 1 | 2016 | 89 | 0.16 | Why? |
Humans | 65 | 2021 | 930598 | 0.16 | Why? |
Complement C3b Inactivator Proteins | 1 | 2016 | 11 | 0.16 | Why? |
Male | 40 | 2021 | 367725 | 0.16 | Why? |
Female | 41 | 2021 | 380317 | 0.16 | Why? |
Immunologic Deficiency Syndromes | 1 | 2021 | 368 | 0.16 | Why? |
Aged | 28 | 2021 | 215776 | 0.16 | Why? |
Phlebotomy | 1 | 2017 | 131 | 0.15 | Why? |
Cell- and Tissue-Based Therapy | 2 | 2017 | 422 | 0.15 | Why? |
Neoplasms | 5 | 2018 | 17251 | 0.15 | Why? |
Lymphoma, B-Cell | 1 | 2017 | 166 | 0.15 | Why? |
Spleen | 2 | 2018 | 877 | 0.14 | Why? |
Genetic Predisposition to Disease | 4 | 2018 | 4027 | 0.14 | Why? |
Follow-Up Studies | 4 | 2021 | 17020 | 0.14 | Why? |
Hematopoietic Stem Cells | 2 | 2017 | 321 | 0.14 | Why? |
Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.14 | Why? |
Sterilization | 1 | 2017 | 294 | 0.14 | Why? |
Fetal Blood | 1 | 2018 | 573 | 0.14 | Why? |
Europe | 6 | 2021 | 12702 | 0.14 | Why? |
Translocation, Genetic | 1 | 2013 | 40 | 0.13 | Why? |
Invasive Fungal Infections | 1 | 2018 | 274 | 0.13 | Why? |
Myeloid-Derived Suppressor Cells | 1 | 2017 | 316 | 0.13 | Why? |
Multimodal Imaging | 1 | 2018 | 534 | 0.13 | Why? |
Combined Modality Therapy | 3 | 2018 | 3395 | 0.13 | Why? |
Gram-Negative Bacteria | 1 | 2017 | 473 | 0.12 | Why? |
Adult | 29 | 2020 | 244371 | 0.12 | Why? |
Neoplasm Proteins | 1 | 2018 | 501 | 0.12 | Why? |
Age Factors | 5 | 2020 | 21039 | 0.12 | Why? |
Gram-Negative Bacterial Infections | 1 | 2017 | 398 | 0.12 | Why? |
Aged, 80 and over | 15 | 2021 | 88759 | 0.12 | Why? |
Prednisone | 1 | 2016 | 652 | 0.12 | Why? |
Sequence Deletion | 1 | 2016 | 674 | 0.11 | Why? |
Renal Insufficiency | 1 | 2018 | 810 | 0.11 | Why? |
Tissue Donors | 2 | 2018 | 1679 | 0.11 | Why? |
Allografts | 3 | 2019 | 761 | 0.11 | Why? |
Point Mutation | 1 | 2013 | 481 | 0.10 | Why? |
Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
Retrospective Studies | 10 | 2021 | 105322 | 0.10 | Why? |
Cryopreservation | 1 | 2013 | 464 | 0.10 | Why? |
Immunosuppressive Agents | 2 | 2018 | 6331 | 0.10 | Why? |
Hypereosinophilic Syndrome | 1 | 2009 | 33 | 0.10 | Why? |
Adolescent | 13 | 2019 | 86841 | 0.10 | Why? |
Genotype | 2 | 2018 | 4697 | 0.10 | Why? |
Unrelated Donors | 2 | 2019 | 187 | 0.09 | Why? |
Macrophages | 1 | 2020 | 2784 | 0.09 | Why? |
Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.09 | Why? |
Young Adult | 12 | 2018 | 93724 | 0.08 | Why? |
Enzyme Inhibitors | 1 | 2018 | 1881 | 0.08 | Why? |
Risk Factors | 9 | 2021 | 71621 | 0.08 | Why? |
Italy | 10 | 2021 | 38444 | 0.08 | Why? |
Needs Assessment | 1 | 2017 | 2352 | 0.08 | Why? |
Thrombocytopenia | 2 | 2017 | 2093 | 0.08 | Why? |
Transplantation, Autologous | 2 | 2018 | 364 | 0.08 | Why? |
Adenine | 2 | 2020 | 463 | 0.08 | Why? |
Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
Piperazines | 1 | 2009 | 445 | 0.08 | Why? |
Skin Neoplasms | 1 | 2019 | 1679 | 0.07 | Why? |
Thrombosis | 3 | 2017 | 7504 | 0.07 | Why? |
Cell Line, Tumor | 3 | 2020 | 3608 | 0.07 | Why? |
Heparin | 1 | 2018 | 2600 | 0.07 | Why? |
Registries | 3 | 2019 | 12327 | 0.07 | Why? |
Lymphocytes | 1 | 2017 | 3056 | 0.07 | Why? |
Prospective Studies | 5 | 2021 | 43301 | 0.07 | Why? |
Bone Marrow | 2 | 2018 | 492 | 0.07 | Why? |
Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
Piperidines | 2 | 2020 | 795 | 0.06 | Why? |
A549 Cells | 2 | 2020 | 2066 | 0.06 | Why? |
Caspases | 1 | 2003 | 156 | 0.06 | Why? |
Aminoglycosides | 1 | 2003 | 94 | 0.06 | Why? |
Leukemia, Myeloid | 1 | 2003 | 76 | 0.06 | Why? |
Protein Kinases | 1 | 2003 | 93 | 0.06 | Why? |
Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
Mutation, Missense | 1 | 2007 | 863 | 0.05 | Why? |
Child | 4 | 2018 | 70012 | 0.05 | Why? |
Risk Assessment | 4 | 2018 | 25439 | 0.05 | Why? |
Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
Hemoglobins | 2 | 2017 | 958 | 0.05 | Why? |
Severity of Illness Index | 5 | 2021 | 48226 | 0.05 | Why? |
Sex Factors | 4 | 2021 | 11014 | 0.05 | Why? |
Transplantation, Haploidentical | 1 | 2019 | 53 | 0.05 | Why? |
Biomarkers | 3 | 2018 | 23361 | 0.05 | Why? |
Cell Proliferation | 2 | 2018 | 1973 | 0.05 | Why? |
Gene Expression Regulation, Leukemic | 1 | 2019 | 31 | 0.05 | Why? |
Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.05 | Why? |
Hypertension | 2 | 2021 | 8895 | 0.05 | Why? |
K562 Cells | 1 | 2018 | 91 | 0.05 | Why? |
Incidence | 5 | 2019 | 25622 | 0.05 | Why? |
Nestin | 1 | 2018 | 12 | 0.05 | Why? |
Mice, Inbred NOD | 1 | 2018 | 134 | 0.05 | Why? |
Cohort Studies | 5 | 2021 | 36005 | 0.05 | Why? |
Antigens, CD19 | 1 | 2018 | 98 | 0.05 | Why? |
Mice, SCID | 1 | 2018 | 225 | 0.05 | Why? |
HL-60 Cells | 1 | 2017 | 60 | 0.04 | Why? |
Quinazolinones | 1 | 2019 | 135 | 0.04 | Why? |
Matrix Metalloproteinase 2 | 1 | 2018 | 85 | 0.04 | Why? |
Serine-Arginine Splicing Factors | 1 | 2017 | 14 | 0.04 | Why? |
Tumor Stem Cell Assay | 1 | 2017 | 12 | 0.04 | Why? |
Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 35 | 0.04 | Why? |
Antigens, CD34 | 1 | 2018 | 125 | 0.04 | Why? |
Isocitrate Dehydrogenase | 1 | 2017 | 33 | 0.04 | Why? |
Leukocyte Count | 3 | 2017 | 3178 | 0.04 | Why? |
Animals | 5 | 2018 | 78931 | 0.04 | Why? |
Hematopoiesis | 1 | 2018 | 168 | 0.04 | Why? |
Fibronectins | 1 | 2018 | 92 | 0.04 | Why? |
Enhancer of Zeste Homolog 2 Protein | 1 | 2017 | 40 | 0.04 | Why? |
Leukemia, Promyelocytic, Acute | 1 | 2017 | 60 | 0.04 | Why? |
Tretinoin | 1 | 2017 | 99 | 0.04 | Why? |
Hydroxyurea | 1 | 2017 | 87 | 0.04 | Why? |
Splenomegaly | 1 | 2016 | 43 | 0.04 | Why? |
Reproducibility of Results | 3 | 2019 | 11304 | 0.04 | Why? |
Comparative Genomic Hybridization | 1 | 2016 | 33 | 0.04 | Why? |
Cytotoxicity, Immunologic | 1 | 2018 | 287 | 0.04 | Why? |
Hep G2 Cells | 1 | 2017 | 391 | 0.04 | Why? |
Child, Preschool | 2 | 2017 | 36283 | 0.04 | Why? |
Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
Interleukin-13 | 1 | 2017 | 204 | 0.04 | Why? |
Histocompatibility Antigens Class II | 1 | 2019 | 383 | 0.04 | Why? |
Mice, Nude | 1 | 2017 | 340 | 0.04 | Why? |
Minnesota | 1 | 2017 | 509 | 0.04 | Why? |
Nuclear Proteins | 1 | 2018 | 321 | 0.04 | Why? |
Janus Kinase 1 | 1 | 2017 | 254 | 0.04 | Why? |
Megakaryocytes | 1 | 2018 | 274 | 0.04 | Why? |
Culture Media | 1 | 2017 | 366 | 0.04 | Why? |
Blood Component Removal | 1 | 2017 | 175 | 0.04 | Why? |
Product Surveillance, Postmarketing | 1 | 2017 | 189 | 0.04 | Why? |
Confidence Intervals | 1 | 2017 | 744 | 0.04 | Why? |
Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.03 | Why? |
Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.03 | Why? |
Time Factors | 4 | 2018 | 31397 | 0.03 | Why? |
Autografts | 1 | 2013 | 78 | 0.03 | Why? |
Cell Movement | 1 | 2018 | 695 | 0.03 | Why? |
Mice | 3 | 2018 | 21357 | 0.03 | Why? |
Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.03 | Why? |
Immunotherapy, Adoptive | 1 | 2018 | 524 | 0.03 | Why? |
Janus Kinase Inhibitors | 1 | 2019 | 682 | 0.03 | Why? |
Post-Exposure Prophylaxis | 1 | 2018 | 472 | 0.03 | Why? |
Purines | 1 | 2019 | 816 | 0.03 | Why? |
Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
Protective Factors | 1 | 2018 | 1720 | 0.03 | Why? |
Herpes Zoster | 1 | 2017 | 331 | 0.03 | Why? |
Hematology | 1 | 2019 | 649 | 0.03 | Why? |
Continuous Positive Airway Pressure | 1 | 2021 | 1187 | 0.03 | Why? |
Predictive Value of Tests | 2 | 2017 | 9537 | 0.03 | Why? |
Immunophenotyping | 1 | 2016 | 1290 | 0.03 | Why? |
Platelet Count | 1 | 2017 | 1381 | 0.03 | Why? |
Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
Gene Frequency | 1 | 2016 | 1210 | 0.03 | Why? |
Mycoses | 1 | 2017 | 589 | 0.03 | Why? |
mRNA Cleavage and Polyadenylation Factors | 1 | 2009 | 3 | 0.03 | Why? |
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 10 | 0.03 | Why? |
Blood Cell Count | 1 | 2016 | 1101 | 0.03 | Why? |
Endothelial Cells | 1 | 2020 | 2048 | 0.03 | Why? |
Infection Control | 1 | 2019 | 23131 | 0.03 | Why? |
Escherichia coli | 1 | 2017 | 1547 | 0.02 | Why? |
Alleles | 1 | 2016 | 1557 | 0.02 | Why? |
Gene Rearrangement | 1 | 2009 | 84 | 0.02 | Why? |
Oncogene Proteins, Fusion | 1 | 2009 | 52 | 0.02 | Why? |
Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.02 | Why? |
Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
Lymphocyte Activation | 1 | 2019 | 2742 | 0.02 | Why? |
Anemia | 1 | 2016 | 789 | 0.02 | Why? |
Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
Protein Binding | 2 | 2017 | 11430 | 0.02 | Why? |
Killer Cells, Natural | 1 | 2018 | 2093 | 0.02 | Why? |
Cluster Analysis | 1 | 2016 | 3001 | 0.02 | Why? |
Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
Noninvasive Ventilation | 1 | 2021 | 2329 | 0.02 | Why? |
Smoking | 1 | 2021 | 3358 | 0.02 | Why? |
Hematocrit | 1 | 2007 | 107 | 0.02 | Why? |
Imatinib Mesylate | 1 | 2009 | 327 | 0.02 | Why? |
Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
Benzamides | 1 | 2009 | 421 | 0.02 | Why? |
Heterozygote | 1 | 2007 | 249 | 0.02 | Why? |
Organ Size | 1 | 2007 | 384 | 0.02 | Why? |
Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
Hypoxia | 1 | 2021 | 3626 | 0.02 | Why? |
Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
Risk | 1 | 2017 | 5288 | 0.02 | Why? |
Pruritus | 1 | 2007 | 215 | 0.02 | Why? |
Myocardial Infarction | 1 | 2021 | 3361 | 0.02 | Why? |
RNA, Messenger | 1 | 2019 | 5131 | 0.02 | Why? |
Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
Disease Susceptibility | 1 | 2017 | 4002 | 0.02 | Why? |
Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
Interphase | 1 | 2003 | 3 | 0.02 | Why? |
Checkpoint Kinase 2 | 1 | 2003 | 5 | 0.02 | Why? |
G2 Phase | 1 | 2003 | 11 | 0.02 | Why? |
Checkpoint Kinase 1 | 1 | 2003 | 10 | 0.02 | Why? |
Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
Bacterial Infections | 1 | 2017 | 2229 | 0.02 | Why? |
World Health Organization | 1 | 2017 | 4213 | 0.02 | Why? |
Tumor Cells, Cultured | 1 | 2003 | 254 | 0.02 | Why? |
Eosinophils | 1 | 2009 | 848 | 0.02 | Why? |
Societies, Medical | 1 | 2019 | 6907 | 0.02 | Why? |
Caspase 3 | 1 | 2003 | 218 | 0.02 | Why? |
Patient Selection | 1 | 2017 | 4560 | 0.02 | Why? |
Drug Administration Schedule | 1 | 2009 | 2324 | 0.01 | Why? |
Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
Surveys and Questionnaires | 2 | 2020 | 43792 | 0.01 | Why? |
CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.01 | Why? |
Immunocompromised Host | 1 | 2017 | 5150 | 0.01 | Why? |
Anti-Bacterial Agents | 1 | 2003 | 10083 | 0.01 | Why? |
Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
Epidemics | 1 | 2020 | 6407 | 0.01 | Why? |
Dose-Response Relationship, Drug | 1 | 2009 | 3776 | 0.01 | Why? |
Amino Acid Substitution | 1 | 2007 | 1706 | 0.01 | Why? |
Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
Phosphorylation | 1 | 2003 | 1060 | 0.01 | Why? |
Immunity, Innate | 1 | 2017 | 6570 | 0.01 | Why? |
Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
Models, Biological | 1 | 2013 | 4907 | 0.01 | Why? |
Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
Sensitivity and Specificity | 1 | 2016 | 22971 | 0.01 | Why? |
Infant | 1 | 2017 | 30274 | 0.01 | Why? |
Apoptosis | 1 | 2003 | 2335 | 0.01 | Why? |
Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |
Cardiovascular Diseases | 1 | 2007 | 11497 | 0.00 | Why? |
Antibodies, Monoclonal, Humanized | 1 | 2003 | 9335 | 0.00 | Why? |